Top News
Radiologic PFS Benefit Observed for Addition of Akt Inhibitor to Abiraterone in Metastatic CRPC
Risk Factors for Poor Prognosis in Patients With Cancer and COVID-19
Racial/Ethnic Disparities in Access to Telehealth Visits: Results From the COVID-19 and Cancer Outcomes Study
Pembrolizumab May Improve Outcomes in Some Rare Sarcomas
No Benefit for Addition of Palbociclib to Adjuvant Endocrine Therapy in Early HR-Positive, HER2-Negative Breast Cancer
Durvalumab-Tremelimumab Plus Chemotherapy Failed to Improve Survival in Pancreatic Cancer Subtype
Neoadjuvant Atezolizumab Plus Chemotherapy Improves pCR in TNBC
First-Line Lorlatinib vs Crizotinib in ALK-Positive Advanced NSCLC
Osimertinib Found to Reduce Risk of CNS Recurrence in Resected EGFRm NSCLC
The COVID-19 Pandemic Is Affecting the Well-Being of Oncologists
Timing and Type of Prior Cancer Therapy May Influence Mortality in Patients With Cancer Diagnosed With COVID-19
EDITORIAL ADVISORY BOARD
E. David Crawford, MD
Jeffrey M. Farma, MD
Featured
-
ESMO 2020 Coverage
Our complete coverage of the European Society for Medical Oncology 2020 virtual meeting. -
Study Documents Real-World Survival Improvement for Non-Small Cell Lung Cancer
An analysis finds that mortality rates for NSCLC are falling faster than incidence rates, which the authors attributed to the introduction of targeted therapies in 2013. -
American Cancer Society Updates Cervical Cancer Screening Guidelines
New guidelines from the American Cancer Society (ACS) appear to move away from the reliance on cytology screening via Pap testing. -
Prostate Cancer Metastasizes by Hijacking a Developmental Epigenetic Program
Localized prostate cancer is thought to metastasize by tapping into a developmental program used by its embryonic ancestors. -
Skin Toxicity Program Can Positively Address EGFR Inhibitor-Related Skin Toxicities
Patients given prophylactic treatment were 94% less likely to require a first rescue treatment for rash and 74% less likely to require a second rescue treatment. -
A New Hope for IL-18 Therapy
Engineered cytokine evades the tumor’s defenses and boosts the production of stem-like polyfunctional T cells. -
Phase 1 Trial Featuring First shRNA-Edited CAR-T Therapy to Begin
FDA approves allogenic CAR T cells targeted at BCMA for phase 1 trial in relapsed/refractory multiple myeloma. -
HRD Score Did Not Predict Benefit of Platinum Therapy in TNBC
The assay may play a role in determining use of other treatments like PARP inhibitors.
More Features
Hepatosplenic T-cell Lymphoma: Recent Progress and Future Considerations
Researchers reviewed the clinical/pathologic aspects of HSTCL and summarized the latest molecular studies and potential novel therapeutic targets.
Communicating With Patients in Oncology About Care During the COVID-19 Pandemic
How to explain adjustments to cancer care due to the COVID-19 pandemic and ease patients’ fears about the impact of those changes.
Can Earlier Mammographic Screenings Affect Mortality Rates?
When should women begin getting mammograms? Guidance can vary based on an individual’s family history or other high-risk identifiers, but physicians advise that women get screened for breast cancer consistently by at least age 50. However, a recent study out of the United Kingdom suggests that starting breast cancer screenings earlier could have a large…
Stereotactic Body Radiotherapy: Past and Future Challenges
Dr Sue Yom discusses the evolution and future of stereotactic body radiotherapy.
Targeted Molecular Therapies for the Treatment of Chronic Lymphocytic Leukemia
Researchers reviewed promising advances in therapy options for patients with CLL and the challenges associated with these new treatments.
-
Loading...
-
Loading...
